Eight patients who were administered Moderna’s vaccine were found to have antibody levels similar to those in blood samples of people who have recovered from Covid-19, according to early results from the study conducted by the National Institutes of Health.
All 45 participants in the study were given three different doses of the vaccine and Moderna said it saw dose-dependent increase in immunogenicity, the ability to provoke an immune response in the body. “We are investing to scale up manufacturing so we can maximise the number of doses we can produce to help protect as many people as we can from SARS-CoV-2,” Moderna chief executive Stéphane Bancel said.and the US government to produce massive quantities of its vaccine.
The vaccine, mRNA-1273, was also found to be generally safe and well tolerated in the early-stage study, the drug developer said. One person in the trial experienced redness around the injection site, which was characterized as a “grade 3” side effect. No serious side effects had been reported, the company said.